Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lachmann

Showing results (261-270 of 426) with videos related to

Pageof 43
Sort By:
Journal of the American Heart Association|June 6, 2022
Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral CenterClaire J Peet, Dorota Rowczenio, Ebun Omoyinmi, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 25, 2014
Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosisDorota Rowczenio, Glenys A Tennent, Janet Gilbertson, et al.
The New England Journal of Medicine|June 8, 2007
Natural history and outcome in systemic AA amyloidosisHelen J Lachmann, Hugh J B Goodman, Janet A Gilbertson, et al.
Annals of the Rheumatic Diseases|June 9, 2016
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II studyMarco Gattorno, Laura Obici, Marco Cattalini, et al.
Blood|October 8, 2005
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosisJulian D Gillmore, Hugh J Goodman, Helen J Lachmann, et al.
Journal of Molecular Biology|August 5, 1990
Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scatteringS J Perkins, K F Smith, S Amatayakul, et al.
Arthritis Research & Therapy|April 12, 2006
The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosusAnthony P Manderson, Francesco Carlucci, Peter J Lachmann, et al.
British Journal of Haematology|October 10, 2017
Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosisSajitha Sachchithanantham, Oscar Berlanga, Azra Alvi, et al.
Clinical and Experimental Immunology|August 16, 2014
Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitroE Lay, S Nutland, J E Smith, et al.
The New England Journal of Medicine|June 7, 2002
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosisHelen J Lachmann, David R Booth, Susanne E Booth, et al.
Pageof 43

Showing results (261-270 of 426) with videos related to

Sort By:
Pageof 43
Journal of the American Heart Association|June 6, 2022
Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral CenterClaire J Peet, Dorota Rowczenio, Ebun Omoyinmi, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 25, 2014
Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosisDorota Rowczenio, Glenys A Tennent, Janet Gilbertson, et al.
The New England Journal of Medicine|June 8, 2007
Natural history and outcome in systemic AA amyloidosisHelen J Lachmann, Hugh J B Goodman, Janet A Gilbertson, et al.
Annals of the Rheumatic Diseases|June 9, 2016
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II studyMarco Gattorno, Laura Obici, Marco Cattalini, et al.
Blood|October 8, 2005
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosisJulian D Gillmore, Hugh J Goodman, Helen J Lachmann, et al.
Journal of Molecular Biology|August 5, 1990
Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scatteringS J Perkins, K F Smith, S Amatayakul, et al.
Arthritis Research & Therapy|April 12, 2006
The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosusAnthony P Manderson, Francesco Carlucci, Peter J Lachmann, et al.
British Journal of Haematology|October 10, 2017
Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosisSajitha Sachchithanantham, Oscar Berlanga, Azra Alvi, et al.
Clinical and Experimental Immunology|August 16, 2014
Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitroE Lay, S Nutland, J E Smith, et al.
The New England Journal of Medicine|June 7, 2002
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosisHelen J Lachmann, David R Booth, Susanne E Booth, et al.
Pageof 43